GlassScriptPhysician profile
Paige Graham
NPI 1811523913
$1,815.86
in general payments reported to CMS, 2019-2025
29 companies · $90.87 in 2025
The $90.87 reported for 2025 was less than what a typical Physician Assistant provider received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $62.30 · 2022: $31.94 · 2023: $1,084 · 2024: $546 · 2025: $90.87.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,722.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,721.62 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $185.01 | 2023-2024 | Lynparza, Epanova |
| Pfizer INC. | $161.95 | 2022-2024 | |
| Seagen INC. | $139.54 | 2023 | Adcetris, Padcev |
| Merck Sharp & Dohme LLC | $121.57 | 2023-2024 | Keytruda |
| Viiv Healthcare Company | $114.20 | 2024 | Cabenuva |
| Ucb, INC. | $85.76 | 2023-2024 | Rystiggo |
| Novartis Pharmaceuticals Corporation | $83.06 | 2023-2024 | |
| Celgene Corporation | $76.90 | 2023-2024 | Reblozyl |
| Daiichi Sankyo INC. | $76.24 | 2023-2024 | Injectafer |
| Myriad Genetic Laboratories, INC. | $71.03 | 2025 | Myrisk |
| Exelixis INC. | $63.17 | 2023 | Cabometyx |
| Regeneron Healthcare Solutions, INC. | $63.10 | 2023-2024 | Libtayo |
| Janssen Pharmaceuticals, INC | $62.30 | 2021 | |
| Karyopharm Therapeutics INC. | $53.45 | 2023-2024 | Xpovio |
| Amgen INC. | $49.17 | 2023 | Lumakras, Vectibix, Xgeva |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alnylam Pharmaceuticals INC. | $45.57 | 2023 | Givlaari |
| Array Biopharma INC | $44.54 | 2023-2025 | Braftovi, Lorbrena, Tukysa |
| Telix Pharmaceuticals | $41.89 | 2023-2024 | Illuccix |
| Janssen Biotech, INC. | $40.41 | 2023-2024 | Erleada, Darzalex |
| Genentech USA, INC. | $38.84 | 2023-2024 | Perjeta, Phesgo, Venclexta |
| Astellas Pharma US INC | $27.34 | 2023 | Xtandi |
| Lilly USA, LLC | $26.51 | 2024 | Jaypirca, Verzenio |
| Emd Serono, INC. | $25.09 | 2024 | |
| Incyte Corporation | $24.08 | 2023 | Jakafi |
| E.R. Squibb & Sons, L.L.C. | $23.23 | 2024 | Opdivo |
| Servier Pharmaceuticals LLC | $22.18 | 2023 | |
| Glaxosmithkline, LLC. | $19.86 | 2023 | Zejula, Jemperli |
| Morphosys, US INC. | $15.79 | 2023 | Monjuvi |
| Taiho Oncology, INC. | $14.08 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Paige Graham listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.